Sera Prognostics Inc (SERA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$2.00-0.50%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Warn: Primary pillar under pressure — Operating losses improve to better than -$9.36M by 2026-Q1: metric not reported.
Sera Prognostics aims to reduce operating losses from about -$9.42M to -$9.36M by 2026-Q1. Revenue, though currently low at $14K in 2026-Q1, could stabilize or improve with management focus. The company has delivered five consecutive earnings beats through 2026-Q1, showing operational progress. Leadership changes are underway to support governance stability.
Revenue declined sharply from $38K in 2025-Q1 to $14K in 2026-Q1, showing weak demand. Operating losses remain large and stagnant near -$9.4M, with net income losses around -$8.4M. The company remains unprofitable with no clear path to sustained growth or profitability.
The market is correcting with no clear consensus on revenue growth or profitability, reflecting uncertainty. Our view is cautious given stagnant losses and declining revenue despite recent earnings beats.
Breaks if: Leadership changes cause material governance or operational disruption
Breaks if: Operating losses worsen beyond -$9.42 million in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on healthcare. The current thesis state reflects uncertainty due to recent earnings misses and a cautious outlook.
The market appears to have priced in ongoing losses and a challenging operational environment. Expectations are low given the recent financial performance, which is below that of its industry peers.
Management is making progress in expanding commercial adoption and regulatory readiness, though financial sustainability remains a concern. The company is currently loss-making, with a slight increase in operating expenses.
The future performance of SERA hinges on the broader healthcare sector's momentum and the outcomes of key sector bellwethers. Additionally, the company's ability to maintain its cash runway and improve earnings will be critical.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Payer momentum indicates strong commercial adoption progress. However, the latest earnings miss shows ongoing financial performance issues.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on reducing operating losses and improving net income over multiple quarters.
Breaks if: Revenue falls below $14,000 in 2026-Q1
Over the next 1 to 3 years, SERA's trajectory will depend on external market conditions and internal execution. Not investment advice.